Inclacumab

• CAT Number: I042525
• CAS Number: 1256258-86-2
• Purity: ≥95%

Inclacumab (Cat No.: I042525) is a fully human monoclonal antibody that targets P-selectin, a cell adhesion molecule involved in inflammation, thrombosis, and vascular injury. By blocking P-selectin, inclacumab inhibits the interaction between endothelial cells, platelets, and leukocytes, thereby reducing vascular inflammation and clot formation. It has been studied in conditions such as acute coronary syndrome and sickle cell disease, where P-selectin plays a key role in disease progression. Inclacumab offers a targeted therapeutic strategy to modulate vascular and inflammatory responses with reduced side effects.

Reference

[1]. Tarasev M, et al. S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE. Hemasphere. 2022 Jan 31;6(Suppl ):3-4.

[2]. Xin Geng, et al. Inclacumab, a Fully Human Anti-P-Selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion. Blood (2020) 136 (Supplement 1): 10–11.

[3]. Kling D, et al. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab–preclinical and clinical studies. Thromb Res. 2013 May;131(5):401-10.
[Content Brief]